{"transactions":[{"id":671454,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":18061,"kind":"person","name":"Lawlor Sally Bridget","position":1,"cik":"0002084407","reported_name":"Lawlor Sally Bridget","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Warrants (Right to Buy)","published_at":"2026-09-02T01:39:14.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":5122,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."}],"balance_after":5122,"derivative":{"exercise_price":6.1,"exercise_date":"2026-08-31","underlying":"ADS","underlying_shares":5122},"source":{"system":"sec-edgar","filing":"0001104659-26-104403","document":"tm2624615-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2084407/000110465926104403/tm2624615-2_4seq1.xml","form_type":"4"}},{"id":671453,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":18061,"kind":"person","name":"Lawlor Sally Bridget","position":1,"cik":"0002084407","reported_name":"Lawlor Sally Bridget","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"ADSs","published_at":"2026-09-02T01:39:14.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":10244,"price":4.88,"value":49990.72,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."}],"balance_after":10684,"source":{"system":"sec-edgar","filing":"0001104659-26-104403","document":"tm2624615-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2084407/000110465926104403/tm2624615-2_4seq1.xml","form_type":"4"}},{"id":916296,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":18061,"kind":"person","name":"Lawlor Sally Bridget","position":1,"cik":"0002084407","reported_name":"Lawlor Sally Bridget","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-02-06T22:24:03.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":85250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":85250,"derivative":{"exercise_price":7.37,"expiration_date":"2036-02-04","underlying":"ADS","underlying_shares":85250},"source":{"system":"sec-edgar","filing":"0001104659-26-011623","document":"tm265448-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2084407/000110465926011623/tm265448-8_4seq1.xml","form_type":"4"}},{"id":982037,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":18061,"kind":"person","name":"Lawlor Sally Bridget","position":1,"cik":"0002084407","reported_name":"Lawlor Sally Bridget","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-12-03T22:39:07.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":10330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":10330,"derivative":{"exercise_price":19.36,"expiration_date":"2035-12-01","underlying":"ADS","underlying_shares":10330},"source":{"system":"sec-edgar","filing":"0001104659-25-118190","document":"tm2532695-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2084407/000110465925118190/tm2532695-1_4seq1.xml","form_type":"4"}}]}